Hybrid hydrogels for pain related indications
in the fields of orthopedics and rheumatology

Company Profile

Chi2Gel® proprietary Hybrid Hydrogel is currently in advanced pre-clinical development in the fields of orthopedics and rheumatology. Current development focus is in patients with painful knee osteoarthritis (OA) where Chi2Knee™ will be indicated for intra-articular injection as visco-supplement (Medical Device).

Chi2Gel’s hydrogel will be later developed in spinal low back pain related to degenerative disc disease (DDD) where Chi2Disc™ will be used in conjunction with our proprietary Disc Restorative device.

What’s new about our solution?

To date, most visco-supplements formulations are based on high molecular weight Hyaluronate that undergoes chemical cross-linking to increase its molecular weight, thus to prolong its intra-articular half life.

Chi2Gel represents a breakthrough Hybrid Hydrogel constituted of purified high molecular weights Chitosans and Hyaluronate. This hydrogel, soluble before injection, polymerizes itself after injection in physiological conditions allowing prolonged intra-articular half life together with excellent rheological performance.

These features should provide physicians and their patients with a simple non-medicinal solution to ameliorate painful osteoarthritic knees.

Chi2Gel Ltd.       38 Habarzel St. Tel Aviv 69710, Israel        Tel: +972 3 993 3227 ext. 4       Fax: +972 3 993 3228       shachar@chi2gel.com